O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTSM.P. Manns, Stephanie Noviello, Stuart C. Gordon et al.|Journal of Hepatology|2014Cited by 20
P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDYJia‐Horng Kao, M.P. Manns, June Heo et al.|Journal of Hepatology|2014Cited by 9